nimotuzumab

a humanized monoclonal antibody that binds to the epidermal growth factor receptor

Also Known As:

Theraloc; theracim-HR3; Immunoglobulin G1, anti-(humanized mouse monoclonal hR3 beta1 chain anti-human epidermal growth factor receptor), disulfide with humanized mouse monoclonal hR3 kappa-chain, dimer

Networked: 295 relevant articles (72 outcomes, 122 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Crombet, Tania: 11 articles (01/2018 - 01/2009)
2.	Prabhash, Kumar: 9 articles (01/2022 - 01/2013)
3.	Noronha, Vanita: 8 articles (01/2022 - 01/2013)
4.	Joshi, Amit: 7 articles (01/2022 - 01/2013)
5.	Fonge, Humphrey: 7 articles (11/2020 - 08/2012)
6.	Sun, Ying: 6 articles (01/2018 - 01/2017)
7.	Bach, Ferdinand: 5 articles (07/2018 - 12/2012)
8.	Iznaga, Normando: 5 articles (01/2018 - 01/2009)
9.	Ma, Jun: 5 articles (01/2018 - 01/2017)
10.	Patel, Usha: 4 articles (01/2022 - 01/2019)

Related Diseases

1.	Neoplasms (Cancer) 05/31/2016 - "However, the optimal dose and administration frequency of nimotuzumab that should be used and which kind of cancer patients will be more benefited from nimotuzumab is still unknown. " 04/01/2019 - "Nimotuzumab combined with standard treatment in locally advanced/metastatic ESCC improved the survival rate and achieved a better tumor response rate without accumulation of toxicity and was well tolerated." 01/01/2022 - "The purpose of this study was to evaluate the safety, overall and progression-free survival, clinical response, and quality of life, in adult patients with inoperable esophageal tumors of epithelial origin treated with nimotuzumab in a practical context. " 03/01/2019 - "The aim of the present study was to investigate the ability of Nimotuzumab to increase radiosensitivity at different delivery times in the mixed cancer cell line Eca109, to determine the optimal delivery time. " 01/01/2016 - "Finally, a fast blood clearance was observed in the biodistribution studies increasing the tumor uptake of Fab(nimotuzumab)- HYNIC-99mTc over time, with tumor/muscle ratios of 3.81 ± 0.50, 5.16 ± 1.97 and 6.32 ± 1.98 at 1 h, 4 h and 24 h post injection. "
2.	Nasopharyngeal Carcinoma 10/02/2020 - "This study aimed to assess the effectiveness and cost-effectiveness of nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). " 11/19/2019 - "The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis." 04/01/2018 - "The clinical data of 75 nasopharyngeal carcinoma patients, who were initially treated with nimotuzumab combined with RT, were collected and retrospectively reviewed from December 2008 to April 2014. " 01/10/2017 - "In this work, we evaluated the feasibility of adding nimotuzumab to chemoradiation in locoregionally advanced nasopharyngeal carcinoma. " 01/01/2015 - "Between December 2009 and December 2013, 38 newly diagnosed patients with stage III-IV nasopharyngeal carcinoma were treated with IMRT and nimotuzumab concomitantly. "
3.	Squamous Cell Carcinoma of Head and Neck 07/01/2012 - "For resectable HNSCC, nimotuzumab plus PF regimen as induction treatment is highly effective for preserving the organ function and the toxicities are well tolerable." 11/01/2021 - "The addition of Nimotuzumab to radical chemoradiation (CRT) improved outcomes in patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing radical CRT in a phase 3 randomized trial. " 05/13/2020 - "This study evaluates the outcome and toxicity of the nimotuzumab-CRT combination for stage III, IVa, and IVb squamous cell carcinoma of the head and neck. " 07/01/2018 - "The aim of this study is to evaluate the efficacy and safety of nimotuzumab when added to standard treatment in unresectable, recurrent, and metastatic squamous cell carcinoma of the head and neck (SCCHN). " 05/01/2014 - "Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients."
4.	Esophageal Neoplasms (Esophageal Cancer) 07/30/2015 - "High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis." 01/01/2013 - "Further studies are required to confirm the therapeutic efficacy of nimotuzumab in esophageal cancer." 03/01/2016 - "Nimotuzumab combined with SIB-IMRT is a safe and effective modality for locally advanced esophageal cancer. " 04/01/2019 - "Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence." 12/01/2017 - "Further prospective studies are required to confirm the therapeutic effectiveness of nimotuzumab in esophageal cancer."
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2011 - "We here summarize the results of preclinical studies as well as of previous and ongoing clinical trials of nimotuzumab for the treatment of non-small cell lung cancer." 10/01/2016 - "We introduced to use nimotuzumab (also known as h-R3) for treating LM of nonsmall cell lung cancer. " 11/09/2010 - "The emerging role of nimotuzumab in the treatment of non-small cell lung cancer." 01/01/2021 - "Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer." 01/01/2014 - "Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study."

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	ErbB Receptors (EGF Receptor)
3.	Cisplatin (Platino)
4.	Cetuximab (Erbitux)
5.	Fluorouracil (Carac)
6.	Docetaxel (Taxotere)
7.	Temozolomide (Temodar)
8.	Gemcitabine
9.	Gefitinib (Iressa)
10.	Platinum

Related Therapies and Procedures

1.	Chemoradiotherapy
2.	Drug Therapy (Chemotherapy)
3.	Radiotherapy
4.	Neoadjuvant Therapy
5.	Therapeutics